HanchorBio to Present at WIC-APAC 2026, Sharing Perspectives on Next-Generation Immunotherapy Design
Alvin Luk, President and CMO of HanchorBio, has been invited to speak at the WIC-APAC 2026, where he will share insights on the clinical validation of CD47–SIRPα in cancer immunotherapy and next-generation multi-checkpoint engineering.
HanchorBio will participate in the World Immunotherapy Council Asia-Pacific Conference (WIC-APAC 2026), to be held on March 28–29, 2026, at the International Convention Center, Chang Yung-Fa Foundation, Taipei, Taiwan. At the conference, Alvin Luk, PhD, MBA, CCRA, President & Chief Medical Officer (CMO) of HanchorBio (Group), and CEO of HanchorBio US, has been invited to present his clinical perspectives on CD47–SIRPα in cancer immunotherapy, as well as the latest trends in next-generation multi-checkpoint engineering.
This invitation not only reflects HanchorBio’s continued commitment to advancing immuno-oncology, but also highlights the company’s growing international visibility in innate immune checkpoint modulation and innovative biologics development.
Event Information
- Event Name: World Immunotherapy Council Asia-Pacific Conference (WIC-APAC 2026)
- Date: March 28–29, 2026
- Venue: International Convention Center, Chang Yung-Fa Foundation, Taipei, Taiwan
Speaker Session
Alvin Luk, PhD, MBA, CCRA | Mar29 12:15-12:50 pm
President & Chief Medical Officer of HanchorBio (Group), CEO of HanchorBio US
Session Title:
Reprogramming the CD47–SIRPα Axis in Cancer Immunotherapy: Clinical Validation and Next-Generation Multi-Checkpoint Engineering
His presentation will discuss from first-generation safety limitations to next-generation innovation. This session highlights how Al-guided SIRPa-Fc engineering unlocks the therapeutic potential of the CD47 axis – demonstrating improved safety profile, clinical validation, and a foundation for multi-checkpoint immune integration.
This session will be moderated by Dr. Peter Mu-Hsin Chang. Dr. Chang is currently an attending physician in the Division of Medical Oncology, Department of Oncology, Taipei Veterans General Hospital, and an Associate Professor at the Institute of Biopharmaceutical Sciences, National Yang Ming Chiao Tung University. He has long specialized in head and neck cancer and medical oncology, and has remained actively involved in clinical trials and new drug development, bringing together frontline clinical practice and translational research experience. His expertise focuses on head and neck cancer, malignant tumor treatment, and immunotherapy-related research, with a strong track record of clinical research publications.
Speaker Profile
Dr. Luk brings extensive industry experience spanning innovative drug R&D, clinical development, regulatory strategy, and global licensing partnerships. He has long focused on the critical path of advancing innovative therapies from research into clinical development and commercialization. Since joining HanchorBio, he has led the company’s clinical and medical strategy while supporting its global development efforts, further strengthening HanchorBio’s competitiveness in innovative biologics development and international collaboration.
His invitation to speak at WIC-APAC also reflects international recognition of his expertise in cancer immunotherapy and translational clinical development.
About WIC-APAC
The World Immunotherapy Council (WIC) is an international organization dedicated to advancing the field of immunotherapy. By connecting alliance societies across multiple countries and regions, WIC has played an important role in promoting cancer immunotherapy research, clinical exchange, and global collaboration. WIC-APAC brings together leading clinical experts, researchers, and healthcare professionals in cancer immunology and immunotherapy across the Asia-Pacific region, and is regarded as one of the region’s most representative professional forums in the field.
This year’s conference features an outstanding lineup of internationally renowned leaders and leading experts from Taiwan. Attendees include medical oncologists, physicians from multiple specialties, clinical nurses, pharmacists, and researchers engaged in both basic and translational science. The event also includes networking and young investigator engagement opportunities designed to foster interdisciplinary collaboration and new research connections.
HanchorBio’s participation and invited presentation at WIC-APAC 2026 underscore the company’s professional standing and active role in the global immuno-oncology innovation community. Through the conference, HanchorBio looks forward to engaging with clinical experts, research partners, and industry leaders from across Asia-Pacific and around the world to advance innovation in cancer immunotherapy, explore cross-border collaboration opportunities, and support translational progress. The company remains committed to leveraging its differentiated engineering platform and clinically driven strategy to advance next-generation biologics with global potential.
About HanchorBio
Based in Taipei, Shanghai, and the San Francisco Bay Area, HanchorBio (7827.TPEx) is a global clinical-stage biotechnology company focused on immuno-oncology and immune-mediated diseases. The company is led by an experienced team with a proven track record in biologics discovery and global development, aiming to reshape the landscape of cancer therapies. HanchorBio’s proprietary Fc-based designer biologics (FBDB™) platform enables the design of multi-functional biologics with diverse targeting modalities, designed to activate both innate and adaptive immune pathways and overcome the current challenges of anti-PD1/PD-L1 immunotherapies. The FBDB™ platform has delivered proof-of-concept data in several in vivo tumor animal models. HanchorBio is advancing a portfolio of innovative biologics designed to address significant unmet medical needs through differentiated molecular configurations in R&D and scalable CMC strategies.
漢康生技受邀於2026世界免疫治療聯盟亞太區大會發表專題演講，分享次世代免疫治療設計觀點
漢康集團總裁暨醫療長兼美國漢康執行長陸英明受邀於世界免疫治療聯盟亞太區大會（WIC-APAC 2026）發表演講，分享腫瘤免疫治療中CD47–SIRPα的臨床驗證與次世代多重檢查點工程設計
漢康生技將參與2026年3月28日至29日在張榮發基金會舉行之世界免疫治療聯盟亞太區大會（WIC-APAC 2026）。本次大會中，漢康集團總裁暨醫療長兼美國漢康執行長陸英明（Alvin Luk, PhD, MBA, CCRA）受邀擔任講者，分享對癌症免疫治療中CD47–SIRPα的臨床見解，以及次世代多重免疫檢查點工程設計的最新趨勢。此次受邀不僅展現漢康生技於腫瘤免疫領域的持續布局，也驗證公司在先天免疫檢查點調控與創新生物藥開發上的國際能見度。
活動資訊
- 活動名稱：世界免疫治療聯盟亞太區大會 （WIC-APAC）
- 日期： 2026年3月28日至29日
- 地點： 台北市張榮發基金會（International Convention Center, Chang Yung-Fa Foundation, Taipei, Taiwan）
講題資訊
陸英明 Alvin Luk, PhD, MBA, CCRA | Mar29 12:15-12:50 pm
漢康集團總裁暨醫療長兼美國漢康執行長
講題：
Reprogramming the CD47–SIRPα Axis in Cancer Immunotherapy: Clinical Validation and Next-Generation Multi-Checkpoint Engineering
重塑 CD47–SIRPα於癌症免疫治療中的角色：臨床驗證與次世代多重免疫檢查點工程設計
本場演講將聚焦CD47–SIRPα作為腫瘤免疫學中關鍵先天免疫檢查點的臨床發展脈絡。內容將回顧第一代 CD47 治療策略在臨床開發過程中所面臨的安全性與療效限制，並進一步探討近年如何透過工程設計，在保留巨噬細胞作用潛力的同時，改善血液學毒性所帶來的挑戰。
此外，陸英明博士也將分享新一代 SIRPα-Fc 策略的發展觀點，說明在 AI 輔助設計與差異化分子工程下，如何朝向更佳安全與具劑量依賴性的抗腫瘤活性作推進。演講亦將討論，當先天免疫檢查點的臨床驗證逐步建立後，如何進一步啟發次世代多重檢查點設計，整合先天與適應免疫路徑，為癌症免疫治療開啟新的開發方向。
本場論壇將由張牧新醫師（Dr. Peter Mu-Hsin Chang） 擔任主持人。張牧新醫師現為台北榮民總醫院腫瘤醫學部腫瘤內科主治醫師，並任國立陽明交通大學生物藥學研究所副教授，長期深耕頭頸癌與腫瘤內科治療，並持續參與臨床試驗及新藥開發，兼具第一線臨床實務與轉譯研究經驗。其專業聚焦於頭頸癌、惡性腫瘤治療及免疫治療相關研究，並累積多篇臨床研究成果。
講者介紹
陸英明博士具備橫跨新藥研發、臨床開發、法規策略與國際授權合作的豐富產業經驗，長期專注於創新療法由研發走向臨床與商業化的關鍵路徑規劃。負責漢康生技之臨床與醫學策略，並推動全球發展布局，強化漢康在創新生物藥開發及國際合作上的整體競爭力。
此次受邀於 WIC-APAC發表演講，亦反映其於腫瘤免疫治療與臨床轉譯領域的專業受到國際會議平台肯定。
關於WIC-APAC
WIC 為聚焦免疫治療發展的國際組織，串聯全球多個國家與地區的聯盟學會，長期致力於促進癌症免疫治療相關研究、臨床交流與國際合作。WIC-APAC 則匯聚亞太地區癌症免疫學與免疫治療領域的重要臨床專家、研究人員及醫療專業人士，是區域內極具代表性的專業論壇之一。
本屆會議講者陣容涵蓋國際知名領袖與台灣重量級專家，與會者包括腫瘤內科醫師、跨專科臨床醫師、臨床護理師、藥師及基礎與轉譯研究學者，並設有交流活動與青年研究者互動，以促進跨領域合作與新研究連結。
此次漢康生技受邀參與並發表專題演講，代表其在全球免疫腫瘤創新研發社群中的專業地位與參與深度，將與來自亞太及全球的臨床專家、研究夥伴與產業先進深入交流，持續推進癌症免疫治療創新，並探索更多跨國合作與臨床轉譯機會。公司也將持續以差異化工程平台與臨床導向策略，推動具全球競爭力的次世代生物藥開發。